Is Axogen (AXGN) Still Undervalued After Its Sharp Rally?

Axogen (AXGN) has drawn investor attention after recent share price moves, with the stock last closing at $50.40. The company operates in peripheral nerve repair and reported annual revenue of $251.17 million.

See our latest analysis for Axogen.

Axogen’s recent 8.53% 1 day share price return and 27.63% 30 day share price return sit alongside a 62.58% year to date share price return. The 1 year total shareholder return of 240.77% and very large 3 year total shareholder return near 7x suggest strong momentum has persisted over multiple years.

If Axogen’s recent move has you thinking more broadly about growth stories in healthcare, it could be worth checking a curated set of specialist opportunities through the 41 healthcare AI stocks.

After such a sharp multi year run in Axogen, the key issue now is whether the current price still offers enough upside to justify the risks, or if the recent excitement has already priced most of that in.

Most Popular Narrative: 5.3% Undervalued

The most widely followed narrative currently places Axogen’s fair value at $53.22 compared with the last close of $50.40. This frames the recent share price strength in the context of projected growth and margins.

Broad-based adoption of Axogen's nerve care algorithm across multiple markets (extremities, oral maxillofacial, breast) and strong momentum in activating high-potential accounts indicate that the addressable market for nerve repair is still substantially underpenetrated. This is cited as a reason for expectations of a long runway for sustained double-digit revenue growth as awareness and adoption rise.

Read the complete narrative.

Curious what sits behind that optimism on Axogen? The narrative focuses on faster top line expansion, improving profitability, and a richer earnings multiple. The specific revenue, margin, and valuation assumptions might surprise you.

Result: Fair Value of $53.22 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Axogen’s heavy reliance on its Avance Nerve Graft, along with the uncertainty surrounding the ongoing Biologics License Application process, could quickly challenge this optimistic narrative.

Find out about the key risks to this Axogen narrative.

Another View on Axogen’s Valuation

While the analyst narrative frames Axogen as about 5.3% undervalued relative to a $53.22 fair value, the current P/S ratio of 10.8x tells a different story. That compares with a fair ratio of 5.2x, the US Medical Equipment industry at 2.9x, and peers at 8x. This gap points to clear valuation risk if growth or margins fall short of expectations, so how comfortable are you paying such a premium for this growth story?

For a closer look at how this pricing gap lines up against fundamentals, including revenue growth and profitability assumptions, it is worth reviewing the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mixed signals around Axogen’s valuation leave you unsure, that is a useful prompt to look closer at the numbers yourself. To get a clearer handle on both the upside story and the concerns that investors are watching, take a moment to review the 1 key reward and 1 important warning sign.

Looking for more investment ideas beyond Axogen?

If Axogen has sharpened your focus on what you own, now is a smart time to scan for other opportunities that could strengthen your portfolio.

• Target potential mispricing by checking companies that screen as attractively valued through the 48 high quality undervalued stocks.
• Boost your focus on resilience by reviewing stocks highlighted in the 76 resilient stocks with low risk scores.
• Hunt for underfollowed potential by scanning the screener containing 17 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com